Mark Foletta has served as Tocagen’s executive vice president and chief financial officer since February 2017. He holds more than 30 years of experience in finance and accounting. Prior to joining Tocagen, Mr. Foletta served as the interim chief financial officer of Biocept, Inc., a publicly held diagnostics company, from August 2015 to July 2016. Mr. Foletta served as senior vice president, finance and chief financial officer of Amylin Pharmaceuticals, Inc., or Amylin, a publicly held biopharmaceutical company, from March 2006 until October 2012 when the company was acquired by Bristol-Myers Squibb, and as vice president, finance and chief financial officer of Amylin from March 2000 until March 2006. Mr. Foletta serves as a member of the board of directors, chairman of the audit committee and member of the nominating and governance committee of Regulus Therapeutics, Inc., a publicly held biopharmaceutical company, as lead director of the board of directors and chairman of the audit committee of DexCom, Inc., a publicly held medical device company and as a member of the board of directors and chairman of the audit committee of Amn Healthcare Services, Inc., a publicly held healthcare workforce and staffing company, and Viacyte, Inc., a privately held biotechnology company. He is a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.